No profile data available.
Kamada Ltd. (KMDA) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Rehovot, Israel, with about 462 full-time employees.
It reported revenue of $180.46 million for fiscal year 2025, up 12.1% from fiscal year 2024, and net income of $20.20 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $54.92 million, up 22.7% from a year before. Its largest business segment, Proprietary Products, brought in 87% of segment revenue in fiscal year 2025; U.S.A was the largest region with 55%. Its market capitalization was $466.30 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Kamada reported $180.46 million in revenue for fiscal year 2025, up 12.1% from $160.95 million in fiscal year 2024. In Q2 2026 revenue was $54.92 million.
Proprietary Products, with $156.21 million or 87% of segment revenue in fiscal year 2025. Next: Distribution (13%).
U.S.A: 55% of revenue by region in fiscal year 2025, followed by Israel (16%).
$466.30 million as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Oculis Holding AG (OCS), Altimmune, Inc. (ALT), Contineum Therapeutics, Inc. (CTNM), Nika Pharmaceuticals, INC (NIKA).